(Q39398243)

11 September 2017

title

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells (English)

1 reference

11 September 2017

author

Ioannis A. Voutsadakis

3

object named as

Ioannis A Voutsadakis

1 reference

11 September 2017

author name string

Konstantinos Tsapakidis

1

1 reference

11 September 2017

Panagiotis J Vlachostergios

2

1 reference

11 September 2017

Christina D Befani

4

1 reference

11 September 2017

Anna Patrikidou

5

1 reference

11 September 2017

Eleana Hatzidaki

6

1 reference

11 September 2017

Danai D Daliani

7

1 reference

11 September 2017

George Moutzouris

8

1 reference

11 September 2017

Panagiotis Liakos

9

1 reference

11 September 2017

Christos N Papandreou

10

1 reference

11 September 2017

publication date

10 February 2012

1 reference

International Journal of Urology

11 September 2017

published in

1 reference

11 September 2017

volume

19

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

565-574

1 reference

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Mammalian bombesin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

NF-kappaB regulation in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Bortezomib as a potential treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

I kappa B kinase is critical for TNF-alpha-induced VCAM1 gene expression in renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Endothelin-1 inhibits apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Complex functions of mutant p53 alleles from human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

21 January 2018

Mechanisms of apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.02967.X

10.1111/J.1442-2042.2012.02967.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference